Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: wgmnoris who wrote (13185)	9/28/2004 10:08:09 PM
From: The Dodgy Ticker	Respond to of 52153

I own some DNAP and hope the announcement you cited bodes well for the company. However, this thread is not a good forum to post news such as this. You would do better to post it on DNAP's SI thread: Subject 36402 Thanks, Bob

To: wgmnoris who wrote (13185)	9/28/2004 10:08:32 PM
From: scaram(o)uche	Respond to of 52153

What the hell does your piss ant post have to do with valuation?

To: wgmnoris who wrote (13185)	9/28/2004 10:11:58 PM
From: The Dodgy Ticker	Respond to of 52153

See what I mean? Bob

To: wgmnoris who wrote (13185)	9/28/2004 10:18:15 PM
From: Biomaven	Read Replies (2) \| Respond to of 52153

Well usually this thread stays away from BB companies, but I guess a $35m investment is enough to give them some credibility. Chronic urticaria is a nasty condition with no existing treatment (short of long-term steroids or immunosuppressives) and so this is something worth keeping an eye on. If only they would stay away from the "Theranostics" mumbo-jumbo. Here's the description of the urticaria drug: Biofrontera drug highly effective in severe chronic urticaria March 30, 2004 Leverkusen, Germany - Biofrontera AG today announced that it obtained a positive interim report of its adaptive Phase II clinical trial for the treatment of severe chronic urticaria. Biofrontera's lead product BF-Derm1, a histidine decarboxylase inhibitor, has strongly reduced the urticaria symptoms in the patients by 30-40 % on average with no relevant side effects. The placebo-controlled, multi-centre study was directed by Dr. Dr. Wolfgang Greb, CEO of Focus Clinical Drug Development GmbH. Severe chronic urticaria is a highly disabling disease, which usually requires an extensive differential diagnosis and is often insufficiently susceptible to symptomatic therapies with antihistamines. “Given the severity and treatment resistance of the disease, we obtained substantial improvements after treatment with BF-Derm1, a compound with a new principle of action for treating severe urticaria. These results strongly confirm our opinion, that the drug should rapidly be developed and registered”, Prof. Dr. Hermann Lübbert, CEO of Biofrontera AG, commented the positive interim results. The independent commission evaluating the interim results consisted of Prof. Hunzelmann, University of Cologne, Prof. Kramer, Focus Immunology Heidelberg, and Prof. Lehmacher, University of Cologne. The commission strongly recommended the continuation of the study due to the excellent benefit risk ratio in this highly disabling disease. The study was accompanied by an extensive safety program, particularly relating to laboratory data, cardiovascular analyses and CNS-effects, in which the drug did not display any toxicity Peter